What do systematic reviews say?

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

• Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  GRADE not reported

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

Summary of findings: single showed no clear difference in change in sputum P aeruginosa density at end of treatment (cfu/g) compared with combination intravenous anti‐pseudomonal antibiotic therapy (moderate certainty).

• Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 76 participants
  Moderate
• Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

The review found no eligible studies for this question.

• Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
• Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

The review found no eligible studies for this question.

• Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

The review found no eligible studies for this question.

• Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: cycled vs culture‐based antibiotic therapy

Summary of findings: cycled probably leads to higher time to next isolation of PA compared with culture‐based antibiotic therapy (moderate certainty).

• Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
  HR 2.04 [1.28, 3.26]
  1 study · 253 participants
  Moderate

Summary of findings: cycled vs culture‐based antibiotic therapy

The review found no eligible studies for this question.

• Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: cycled vs culture‐based antibiotic therapy

• Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 131 participants
  Very low

Summary of findings: cycled vs culture‐based antibiotic therapy

• Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 253 participants
  Moderate

Summary of findings: cycled vs culture‐based antibiotic therapy

The review found no eligible studies for this question.

• Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: cycled vs culture‐based antibiotic therapy

Summary of findings: cycled showed no clear difference in adverse events: severe adverse events (total) compared with culture‐based antibiotic therapy (moderate certainty).

• Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
  RR 0.65 [0.39, 1.11]
  1 study · 253 participants
  Moderate

Summary of findings: cycled vs culture‐based antibiotic therapy

Summary of findings: cycled showed no clear difference in emergence of novel bacteria: isolation of novel gram negative… compared with culture‐based antibiotic therapy (moderate certainty).

• Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
  RR 1 [0.67, 1.5]
  1 study · 253 participants
  Moderate

Insulin vs placebo

• Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 39 participants
  Very low

Insulin vs placebo

Summary of findings: insulin showed no clear difference in FEV1 % predicted: change from baseline compared with placebo (low certainty).

• Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
  MD 1.2
  1 study · 39 participants
  Low

Insulin vs placebo

Summary of findings: insulin showed no clear difference in FVC % predicted: change from baseline compared with placebo (low certainty).

• Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
  MD 0.6
  1 study · 39 participants
  Low

Insulin vs placebo

Summary of findings: insulin showed no clear difference in BMI(kg/m²): change from baseline compared with placebo (low certainty).

• Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
  MD 0.41
  1 study · 39 participants
  Low

Insulin vs placebo

Summary of findings: insulin showed no clear difference in hypoglycemia: number of episodes compared with placebo (low certainty).

• Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
  RR 9.23 [0.53, 159.14]
  1 study · 55 participants
  Low

Summary of findings: low‐dose vs high‐dose PERT

• Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 17 participants
  Very low

Summary of findings: low‐dose vs high‐dose PERT

The review found no eligible studies for this question.

• Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: low‐dose vs high‐dose PERT

The review found no eligible studies for this question.

• Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found